Establish a platform for direct dialogue between research results and the investment community, and promote the transformation of pharmaceutical innovation results

——The first China Pharmaceutical Innovation and investment conference is about to open in a grand way Source: China pharmaceutical promotion association held the first "China Pharmaceutical Innovation and investment conference" (hereinafter referred to as "innovation and investment conference") press conference in Beijing on August 22, 2016, from November 14 to 16 The "innovation and investment conference" held in Suzhou Industrial Park on May 1 was kicked off "Innovation investment conference" aims to encourage the innovation and development of the pharmaceutical industry by building a bridge between the investment community and the pharmaceutical innovation community Leaders of China Pharmaceutical Innovation Promotion Association (hereinafter referred to as "China pharmaceutical promotion association") and Suzhou Industrial Park attended the conference Song Ruilin, executive chairman of China pharmaceutical promotion association, made a background introduction on the innovation of pharmaceutical industry and the introduction of social capital Yang Zhiping, director of Suzhou Industrial Park Management Committee, introduced the development of the park Song Ruilin, executive chairman and Yang Zhiping, director, answered questions from reporters Song Ruilin, executive chairman of China pharmaceutical promotion association, made a background introduction on the innovation of pharmaceutical industry and the introduction of social capital Yang Zhiping, director of Suzhou Industrial Park Management Committee, introduced the development of Suzhou Industrial Park Song Ruilin and Yang Zhiping, executive chairman of China pharmaceutical promotion association, answered questions from reporters on the preparation of the meeting 1、 Why to hold communication and exchange meeting between pharmaceutical industry and investment industry? What is the background and reason of the meeting? What are the problems of pharmaceutical innovation in China? A: since the 18th National Congress of the Communist Party of China, the CPC Central Committee and the State Council have formulated and issued a series of important documents and policies, placing innovation drive in an important position to maintain the fate of the country, and making it clear that the core support of national strength is the ability of scientific and technological innovation While encouraging innovation, we should also support the transformation of scientific and technological achievements, so that scientific and technological innovation can be transformed into productivity as soon as possible The outline of national innovation driven development strategy and the opinions of the CPC Central Committee and the State Council on deepening the reform of investment and financing system clearly put forward that we should expand the function of multi-level capital market to support innovation, vigorously develop direct financing and broaden the financing channels of investment projects; We will give full play to the role of funds in the transformation of scientific and technological achievements, the innovation of small and medium-sized enterprises, and the cultivation of emerging industries, and guide and drive the innovation of social capital investment 2015 8 In June, the amendment to the law of the people's Republic of China on promoting the transformation of scientific and technological achievements was issued It was proposed that the transformation of scientific and technological achievements should respect the laws of the market, give full play to the main role of enterprises, encourage scientific research institutions to transfer scientific and technological achievements to enterprises or other organizations by means of transfer, licensing or pricing investment, etc., and make important contributions to the accomplishment and transformation of professional scientific and technological achievements Other personnel of the company will be rewarded, and the transformation method and the proportion of encouragement will be specified In October 2015, general secretary Xi Jinping proposed at the eleventh meeting of the central financial and economic leading group, while moderately expanding the total demand, we should focus on strengthening the structural reform of the supply side, strive to improve the quality and efficiency of the supply system, enhance the driving force for sustained economic growth, and promote the overall leap of our social productivity level The above major decisions show that China's economic governance ideas have undergone major adjustments Through the combination of science and technology and economy, we will promote the upgrading of economic quality and efficiency In May this year, the outline of national innovation driven development strategy (hereinafter referred to as the outline) issued by the CPC Central Committee and the State Council clearly pointed out: expand the function of multi-level capital market to support innovation, actively develop angel investment, expand the scale of venture capital investment, and use Internet finance to support innovation We will give full play to the role of funds in the transformation of scientific and technological achievements, the innovation of small and medium-sized enterprises, and the cultivation of emerging industries, and guide and drive the innovation of social capital investment The outline clearly indicates the close relationship between investment and innovation, which is of great significance The opinions of the Central Committee of the Communist Party of China and the State Council on deepening the reform of investment and financing system issued in July this year clearly requires that we should rely on the multi-level capital market system, broaden the financing channels of investment projects, and increase the financial support for investment projects of seed stage and start-up stage enterprises in various ways, specifically for "mass entrepreneurship and innovation" The project provides comprehensive financing services such as equity, creditor's rights and credit loans 2015 is an extraordinary year for China's pharmaceutical industry Changes have taken place in drug regulation A series of major initiatives, such as the reform of the review and approval system, the pilot of the listing license system, the evaluation of the consistency of generic drugs, the liberalization of drug prices and the adjustment of the medical insurance catalogue, show that China's pharmaceutical industry is ushering in a spring! At the beginning of this year, the China Council for the promotion of drugs undertook the third-party effectiveness evaluation of the national "11th Five Year Plan" and "12th Five Year Plan" major special support projects, entrusted by the National Office of major new drugs projects Through the evaluation, we are pleased to see the great progress made in China's pharmaceutical innovation Since the 11th Five Year Plan and the 12th Five Year Plan, the state has invested about 12.8 billion yuan in supporting the research and development of innovative drugs and the construction of innovation capacity through major special projects for new drug creation, and achieved significant results; a number of innovative varieties have been put on the market, and the national innovation capacity has been significantly improved, forming an industry development trend with innovation as the core However, there are still some problems in China's pharmaceutical innovation, such as insufficient investment and transformation rate, especially the lack of social capital to support pharmaceutical innovation According to the data, the proportion of major special support funds and social capital investment for national new drug development during the 11th Five Year Plan and 12th Five Year Plan period is 1:1.3, only 1 / 5 of that in developed countries There is a disconnect between innovation and capital market in China's pharmaceutical innovation On the one hand, a large number of pharmaceutical innovation projects, including major special support projects, are in urgent need of financial support; on the other hand, the investment community is eager to find promising projects The experience of the world's pharmaceutical innovation powers proves that the close combination of capital market and innovation activities is one of the core conditions for the success of innovation We urgently need to take actions to provide communication and exchange services for pharmaceutical innovation and investment institutions, build platforms and bridges, encourage and promote close cooperation between social capital and Chinese pharmaceutical innovation; this is not only to promote the realization of capital services for the real economy, but also an important measure of supply side reform 2: Why do you choose Suzhou Industrial Park? China Council for the promotion of medicine is a social organization approved by the Ministry of civil affairs, which is composed of domestic pharmaceutical innovation enterprises, R & D institutions and investment institutions Adhering to the tenet of "innovation, industrialization and internationalization", it has been committed to promoting the development of pharmaceutical innovation in China Suzhou Industrial Park is an important cooperation project between the governments of China and Singapore In recent years, the park has increased its support for biomedical innovation, attracted a group of independent innovation leading enterprises with core intellectual property rights and strong market competitiveness, and formed a biomedical industry ecosystem with high degree of agglomeration, distinctive characteristics, strong momentum and great vitality It is becoming a leading biomedical industry ecosystem The leading innovation and entrepreneurship base and technology innovation center of biomedical industry in China In order to respond to and implement the spirit of innovation driven program and investment and financing reform opinions, we should leverage social capital to invest in the field of pharmaceutical innovation in China, realize capital service in the real economy, promote the timely and effective transformation of clinical urgently needed innovation project results, benefit the majority of patients and promote the healthy development of the pharmaceutical industry After careful consultation with Suzhou Industrial Park, Jiangsu Province, and an agreement reached on June 12, CFDA will hold "2016 China Pharmaceutical Innovation and investment conference" in Suzhou from November 14 to 16, 2016 This is the first high-level and high-level pharmaceutical innovation investment conference held in China The conference will build a direct dialogue platform for the effective docking of innovation research results and the investment community based on the concept of resource allocation determined by the market and international successful experience 3 What is the theme of this conference? The theme of this conference is "to promote the combination of social capital and innovation and improve the innovation ability of the pharmaceutical industry" In three days, the conference will focus on and discuss the policy of China's pharmaceutical industry, the trend of new drug research and development, and the investment in the pharmaceutical field 4 Which institutions supported this meeting? Since the preparation of this conference, the pharmaceutical industry and the investment community have paid extensive attention to it and caused a warm response The investment community, the securities industry, fund companies and pharmaceutical innovation enterprises and institutions have expressed their expectations for the conference As of today, the China Academy of Sciences, the Chinese Academy of Medical Sciences, the Chinese Academy of traditional Chinese medicine, the Chinese Academy of Military Medical Sciences, and the China Organization Department thousand talents program expert Association have been the supporting units of the conference, which has also received the participation and support of JP Morgan, a famous international investment bank People's daily, people's Daily Overseas Edition, health news, pharmaceutical economic news, China Securities News, etc will be the media support units of the conference, reporting the whole process of the conference In addition, a number of heavyweight support units are in the process of confirmation 5 What are the important contents of this conference? In this conference, academician sang Guowei, vice chairman of the Standing Committee of the 11th National People's Congress and chief engineer of major new drug technologies, was specially invited to attend the conference and give a keynote speech At the conference, three vice chief engineers of major new drug technologies were also invited: academician Zhang Boli, president of the Chinese Academy of Sciences, academician Chen Kaixian, President of Shanghai Association of science and technology, and Cao Xue, President of the Chinese Academy of Medical Sciences Academician Tao attended the opening ceremony and will hold the first public dialogue between pharmaceutical innovation scientists and investors on the issue of pharmaceutical innovation investment at the conference The speakers at the conference also included: Gwan sun Lee, President and CEO of Korean American Pharmaceutical Co., Ltd., and Mary Lynne Hedley, President and COO of American tesaro company JP Morgan of the United States said it would send global executives to the meeting and deliver a speech at the opening ceremony This is a high-end gathering of China's top pharmaceutical innovation scientists and researchers with the international and domestic investment community It will truly realize the dialogue between innovation scientists and investment interface, which is worth looking forward to! 6 What is the scale of this meeting? Who are the participants? Please introduce the meeting form and schedule The conference will bring together more than 100 investment institutions, more than 100 pharmaceutical listed companies and more than 300 pharmaceutical innovation enterprises and institutions The number of participants is expected to reach 1500 The conference will be divided into three days, including the opening ceremony of the conference, roadshows of innovative enterprises and projects and related forums According to the schedule of the meeting, the opening ceremony of the meeting will be held on the morning of November 14 During the meeting, there will also be 12 roadshow reports, which are divided into special sessions for listed companies and special sessions for innovative drugs More than 100 pharmaceutical enterprises and main principals of drug R & D units will introduce their own innovative projects Among them, the global first meeting of clinical data of major new drug innovation projects will also be arranged 7 How is the registration fee charged for this meeting? The first 150 pharmaceutical enterprises and the first 80 investment institutions applying for registration before September 31 and passing the examination will be granted the preferential treatment free of the conference registration fee, first come first served Members of the China Council for the promotion of drugs are exempt from the registration fee Head